IP Library Granted Patent US 8,158,120
Granted Patent B2
US 8,158,120 · App. 12/725,867 · Granted Apr 17, 2012

Cardiac muscle repair or regeneration using bone marrow-derived stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,120
App. No.
12/725,867
Granted
Apr 17, 2012
Kind
B2
Abstract

Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

Claims (11)

1. A method of improving left ventricular ejection fraction in a patient comprising the step of:

administering to the patient adult allogeneic mesenchymal stem cells in an amount effective to improve ventricular ejection fraction.

2. The method of claim 1 , wherein the stem cells are administered intravenously or intraarterially.

3. The method of claim 1 , wherein the mesenchymal stem cells are administered in a pharmaceutically acceptable liquid carrier.

4. The method of claim 3 , wherein the pharmaceutically acceptable carrier comprises an isotonic liquid.

5. The method of claim 4 , wherein the isotonic liquid comprises phosphate buffer saline, physiological saline, culture medium, or 5% dextrose in water.

6. The method of claim 4 , wherein the pharmaceutically acceptable carrier comprises phosphate buffer saline.

7. The method of claim 1 , wherein the mesenchymal stem cells are administered in a suspension containing about 10×10 6 to about 40×10 6 mesenchymal stem cells per ml.

8. The method of claim 7 , wherein the cell suspension is administered in an amount of about 20 μl to about 150 ml.

9. The method of claim 7 , wherein the cell suspension is at least about 20 μl.

10. The method of claim 7 , wherein the cell suspension is at least about 500 μl.

Assignments (4)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2013
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 031533/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2010
From: PITTENGER, MARK F.; GORDON, STEPHEN L.; MACKAY, ALASTAIR MORGAN
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 024100/0006 →